Primary biliary cholangitis (PBC)
Drug research and approvals for primary biliary cholangitis (PBC): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 33 studies of primary biliary cholangitis (PBC) are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, FDA has 3 approved and 12 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 33
- Trials authorized in Canada: 18
- FDA orphan approvals: 3
- EU medicines: 3
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisNCT07841977 · Phase 2 · Gilead Sciences · starts Oct 1, 2026
- Austrian PBC RegistryNCT07598669 · Not reported · Medical University of Vienna · starts Mar 18, 2026
- Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During PregnancyNCT07556913 · Not reported · Ipsen · starts Jul 29, 2026
- Biochemical Response and Clinical Outcomes in Patients With PBCNCT07449793 · Not reported · RenJi Hospital · starts Feb 1, 2026
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyNCT07424677 · Phase 3 · Zydus Therapeutics Inc. · starts Aug 11, 2026
- FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyNCT07296458 · Phase 3 · Xijing Hospital of Digestive Diseases · starts Dec 15, 2025
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCANCT07282353 · Phase 3 · Cascade Pharmaceuticals, Inc · starts Dec 1, 2025
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar…NCT07216235 · Phase 3 · Zydus Therapeutics Inc. · starts Mar 24, 2026
- Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and…NCT07205874 · Not reported · Hospital Universitario La Paz · starts Sep 15, 2025
How its trials ended
181 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 51 whose ending is known, 43% met their primary endpoint, 8% missed it and 49% stopped early.
- Completed, result not reported5329%
- Ongoing5028%
- Status unknown2715%
- Met its primary endpoint2212%
- Stopped: other or unclear137%
- Stopped: sponsor or business decision63%
- Missed its primary endpoint42%
- Stopped: enrollment or feasibility32%
- Stopped: safety21%
- Stopped: lack of efficacy11%
| Sep 2, 2026 | A phase 2 proof of-concept study with a randomized, double blind, placebo-controlled period, followed by an active treatment extension period to assess the…Seladelpar (GS-2024) / Cilofexor (GS-9674) | Gilead Sciences | Pending |
| May 25, 2026 | A phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of elafibranor in adult participants with…Elafibranor (IPN60190) | Ipsen | Pending |
| Jan 13, 2025 | A 52-week, double-blind, placebo-controlled, randomized, phase 3 study intended to determine the effects of seladelpar on normalization of alkaline phosphatase…Seladelpar | Gilead Sciences | Closed |
| Oct 9, 2024 | A randomized, double-blind, placebo-controlled, study to evaluate the effect of seladelpar on clinical outcomes in patients with primary biliary cholangitis…Seladelpar (MBX-8025) | Gilead Sciences | Ongoing |
| Jun 4, 2024 | A phase 3, open-label, long-term safety extension study evaluating the safety and tolerability of the fixed-dose combination of obeticholic acid and…Obeticholic acid-bezafibrate | Alfasigma | Closed |
| Feb 2, 2024 | A phase III randomised, parallel-group, double-blind, placebo-controlled, two-arm study to evaluate the efficacy and safety of elafibranor 80 mg on long-term…Elafibranor (IPN60190) | Ipsen | Ongoing |
| Jan 11, 2024 | A phase 2, randomized, placebo-controlled, parallel group, multicenter 12-week study with a 52-week extension to evaluate the efficacy and safety of two doses…Pemafibrate (K-808) | Kowa Research Institute, Inc | Closed |
| Nov 14, 2023 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of volixibat in the treatment of cholestatic pruritus in patients with…Volixibat | Mirum Pharmaceuticals | Ongoing |
| Aug 3, 2022 | Randomized, double-blind, placebo-controlled study to evaluate the effects of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis or…EP547 | Escient Pharmceuticals Inc | Closed |
| Mar 25, 2022 | A phase 2a, double-blind, randomized, active controlled, parallel group study evaluating the efficacy, safety, and tolerability of bezafibrate administered in…Obeticholic acid / Bezafibrate | Alfasigma | Closed |
| Mar 17, 2026 | LynavoyTreatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients | Intercept Pharmaceuticals, Inc. (A wholly owned subsidiary of Alfasigma S.p.A.) | Approved |
| Aug 14, 2024 | LivdelziTreatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate… | Gilead Sciences, Inc. | Approved |
| Jun 10, 2024 | IqirvoTreatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate… | Ipsen Bioscience Inc. | Approved |
| Jul 24, 2025 | Selective nonsteroidal FXR agonistTreatment primary biliary cholangitis | Cascade Pharmaceuticals, Inc | Designated |
| Dec 30, 2024 | PDC-E2-peptide drug substanceTreatment of primary biliary cholangitis | COUR Pharmaceuticals Development Company, Inc. | Designated |
| Oct 23, 2024 | VolixibatTreatment of primary biliary cholangitis | Mirum Pharmaceuticals, Inc. | Designated |
| Jul 25, 2024 | Navacim, a human-specific peptide-major histocompatibility…Treatment of primary biliary cholangitis | Parvus Therapeutics U.S., Inc. | Designated |
| Apr 20, 2023 | PemafibrateTreatment of primary biliary cholangitis | Kowa Research Institute, Inc. | Designated |
| Jan 12, 2023 | GolexanoloneTreatment of primary biliary cholangitis | Umecrine Cognition AB | Designated |
| Feb 1, 2021 | (2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl…Treatment of Primary Biliary Cholangitis | Future Medicine Co., Ltd. | Designated |
| Jan 26, 2021 | Saroglitazar magnesiumTreatment of Primary Biliary Cholangitis (PBC) | Zydus Therapeutics Inc. | Designated |
| Oct 16, 2020 | SetanaxibTreatment of primary biliary cholangitis | Calliditas Therapeutics AB | Designated |
| Mar 30, 2020 | Combination of p-Tolylmethylcarbinol nicotinic acid ester…Treatment of primary biliary cholangitis | RNR BioMedical Inc. | Designated |
| Mar 9, 2020 | Glucagon-like peptide-1/Glucagon/Gastric inhibitory…Treatment of primary biliary cholangitis | Hanmi Pharmaceutical Company, Ltd. | Designated |
| Feb 11, 2019 | BudesonideTreatment of primary biliary cholangitis | Asahi Kasei Therapeutics AB | Designated |
| Oct 22, 2026 | LynavoyLinerixibat · orphan | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Sep 19, 2024 | IqirvoElafibranor · orphan | Ipsen Pharma | EMA ↗ |
| not available | Lyvdelzi (previously Seladelpar Gilead)Seladelpar lysine dihydrate · orphan | Gilead Sciences Ireland Unlimited Company | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA